Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Bristol-Myers Squibb Company
BMY
$66.29
Name : Bristol-Myers Squibb Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $135,391,125,504.00
EPSttm : 4.54
finviz dynamic chart for BMY
Bristol-Myers Squibb Company
$66.28
1.97%
$1.33
BMY — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.57

Margin Of Safety %

16

Put/Call OI Ratio

0.94

EPS Next Q Diff

-0.45

EPS Last/This Y

3.48

EPS This/Next Y

-0.39

Price

67.61

Target Price

66.04

Analyst Recom

2.45

Performance Q

15.95

Upside

-12.7%

Beta

0.23

Ticker: BMY




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-21BMY60.920.791.25619945
2026-07-22BMY60.770.810.46629560
2026-07-23BMY61.530.810.25636340
2026-07-24BMY62.10.810.64638620
2026-07-27BMY62.560.810.54630105
2026-07-28BMY63.620.820.72635192
2026-07-29BMY63.410.821.15640420
2026-07-30BMY64.870.821.46661175
2026-07-31BMY65.30.881.48726278
2026-08-03BMY65.460.921.07711174
2026-08-04BMY65.90.900.61706005
2026-08-05BMY63.640.920.93713267
2026-08-06BMY64.150.910.73715696
2026-08-07BMY64.710.910.95719700
2026-08-10BMY64.860.930.54701400
2026-08-11BMY63.610.930.81708608
2026-08-12BMY63.710.940.58747633
2026-08-13BMY64.640.940.80751493
2026-08-14BMY63.840.940.54752411
2026-08-17BMY64.270.950.97739762
2026-08-18BMY66.080.940.29746941
2026-08-19BMY67.420.940.20750913
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-21BMY60.929.04515.76.34
2026-07-22BMY60.759.34325.36.34
2026-07-23BMY61.539.34516.36.34
2026-07-24BMY62.119.34481.06.34
2026-07-27BMY62.549.34450.56.34
2026-07-28BMY63.639.34571.86.34
2026-07-29BMY63.139.34271.26.34
2026-07-30BMY64.889.34710.26.34
2026-07-31BMY65.33-1.44454.36.34
2026-08-03BMY65.43-1.42150.56.34
2026-08-04BMY65.43-1.42150.56.34
2026-08-05BMY63.635.32426.06.83
2026-08-06BMY64.165.32988.26.83
2026-08-07BMY64.706.43758.66.95
2026-08-13BMY64.656.43845.26.95
2026-08-14BMY63.856.43470.86.95
2026-08-17BMY64.646.43816.16.95
2026-08-18BMY66.096.33951.46.95
2026-08-19BMY67.616.33968.06.95
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-21BMY-0.46-0.041.99
2026-07-22BMY-0.46-0.041.99
2026-07-23BMY-0.46-0.041.99
2026-07-24BMY-0.46-0.041.99
2026-07-27BMY-0.460.282.21
2026-07-28BMY-0.460.282.21
2026-07-29BMY-0.460.282.21
2026-07-30BMY-0.460.282.21
2026-07-31BMY-0.460.282.21
2026-08-03BMY-0.460.332.21
2026-08-04BMY-0.460.332.21
2026-08-05BMY-0.460.332.21
2026-08-06BMY-0.460.332.21
2026-08-10BMY-0.460.522.21
2026-08-11BMY-0.460.522.21
2026-08-12BMY-0.460.522.57
2026-08-13BMY-0.460.522.57
2026-08-14BMY-0.460.522.57
2026-08-17BMY-0.46-0.262.57
2026-08-18BMY-0.40-0.262.57
2026-08-19BMY-0.40-0.262.57
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

2.04

Avg. EPS Est. Current Quarter

1.73

Avg. EPS Est. Next Quarter

1.59

Insider Transactions

-0.4

Institutional Transactions

-0.26

Beta

0.23

Average Sales Estimate Current Quarter

12662

Average Sales Estimate Next Quarter

12695

Fair Value

78.26

Quality Score

90

Growth Score

53

Sentiment Score

91

Actual DrawDown %

17

Max Drawdown 5-Year %

-47.7

Target Price

66.04

P/E

14.89

Forward P/E

10.32

PEG

P/S

2.81

P/B

6.19

P/Free Cash Flow

12.07

EPS

4.54

Average EPS Est. Cur. Y​

6.95

EPS Next Y. (Est.)

6.56

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

18.87

Relative Volume

1.11

Return on Equity vs Sector %

15

Return on Equity vs Industry %

5.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.62

EBIT Estimation

3968
BMY Healthcare
$67.61
📉
Swing / Pullback
Buy the dip on strong trends
44 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
4/15
Valuation
8/20
TP/AR
2/10
Options
4/10
RSI
68.9
Range 1M
90.9%
Sup Dist
3.5%
🚀
Momentum Growth
Ride accelerating trends
52 /100
WEAK
Momentum
21/25
Growth
13/30
Estimates
6/20
Inst/Vol
5/15
Options
7/10
EPS Yr
12.7%
EPS NY
-5.4%
52W%
96.9%
💎
Long-Term Value
Quality companies, undervalued
51 /100
WEAK
🟡 HOLD +17.3% upside
Quality
24/30
Valuation
9/30
Growth
11/25
Stability
3/10
LT Trend
4/5
Upside
+17.3%
Quality
90
MoS
16%
BMY — P/E HistoricalDrug Manufacturers - General
Bristol-Myers Squibb Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 32500
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
BMY

Latest News

Caricamento notizie per BMY
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading